Due to a production error, 24 references with more than six authors were listed in the Reference list without “et al.” The references affected are Bouaboula et al. (1993, 1996); Felder et al. (1995); Galiegue et al. (1995); Favata et al. (1998); Portier et al. (1999); Kilts et al. (2002); Karsak et al. (2005); Wright et al. (2005); Ofek et al. (2006); Jiang et al. (2007); Valant et al. (2008); Cencioni et al. (2010); Hurst et al. (2010); Schuehly et al. (2011); van der Stelt et al. (2011); Kleyer et al. (2012); Odan et al. (2012); Shonberg et al. (2013); Brailoiu et al. (2014); Herenbrink et al. (2016); Finlay et al. (2017); Soethoudt et al. (2017) and Yrjölä et al. (2015).
The publisher apologizes for this mistake. The original version of this article has been updated.
References
1
BouaboulaM.Poinot-ChazelC.MarchandJ.CanatX.BourrieB.Rinaldi-CarmonaM.et al. (1996). Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem.237, 704–711. 10.1111/j.1432-1033.1996.0704p.x
2
BouaboulaM.RinaldiM.CarayonP.CarillonC.DelpechB.ShireD.et al. (1993). Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem.214, 173–180. 10.1111/j.1432-1033.1993.tb17910.x
3
BrailoiuG. C.DeliuE.MarcuJ.HoffmanN. E.Console-BramL.ZhaoP.et al. (2014). Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry53, 4990–4999. 10.1021/bi500632a
4
CencioniM. T.ChiurchiuV.CatanzaroG.BorsellinoG.BernardiG.BattistiniL.et al. (2010). Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE5:e8688. 10.1371/journal.pone.0008688
5
FavataM. F.HoriuchiK. Y.ManosE. J.DaulerioA. J.StradleyD. A.FeeserW. S.et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem.273, 18623–18632. 10.1074/jbc.273.29.18623
6
FelderC. C.JoyceK. E.BrileyE. M.MansouriJ.MackieK.BlondO.et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol.48, 443–450.
7
FinlayD. B.CawstonE. E.GrimseyN. L.HunterM. R.KordeA.VemuriV. K.et al. (2017). Gas signalling of the CB1 receptor and the influence of receptor number. Br. J. Pharmacol.174, 2545–2562. 10.1111/bph.13866
8
GaliegueS.MaryS.MarchandJ.DussossoyD.CarriereD.CarayonP.et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem.232, 54–61.
9
HerenbrinkC. K.SykesD. A.DonthamsettiP.CanalsM.CoudratT.ShonbergJ.et al. (2016). The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun.7:10842. 10.1038/ncomms10842
10
HurstD. P.GrossfieldA.LynchD. L.FellerS.RomoT. D.GawrischK.et al. (2010). A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J. Biol. Chem.285, 17954–17964. 10.1074/jbc.M109.041590
11
JiangL. I.CollinsJ.DavisR.LinK.-M.DeCampD.RoachT.et al. (2007). Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-Phosphate/G(13) pathway. J. Biol. Chem.282, 10576–10584. 10.1074/jbc.M609695200
12
KarsakM.Cohen-SolalM.FreudenbergJ.OstertagA.MorieuxC.KornakU.et al. (2005). Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol. Genet.14, 3389–3396. 10.1093/hmg/ddi370
13
KiltsJ. D.ConneryH. S.ArringtonE. G.LewisM. M.LawlerC. P.OxfordG. S.et al. (2002). Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J. Pharmacol. Exp. Ther.301, 1179–1189. 10.1124/jpet.301.3.1179
14
KleyerJ.NicolussiS.TaylorP.SimonelliD.FurgerE.AnderleP.et al. (2012). Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. Biochem. Pharmacol.83, 1393–1412. 10.1016/j.bcp.2012.02.014
15
OdanM.IshizukaN.HiramatsuY.InagakiM.HashizumeH.FujiiY.et al. (2012). Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. Bioorg. Med. Chem. Lett.22, 2803–2806. 10.1016/j.bmcl.2012.02.072
16
OfekO.KarsakM.LeclercN.FogelM.FrenkelB.WrightK.et al. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. U.S.A.103, 696–701. 10.1073/pnas.0504187103
17
PortierM.Rinaldi-CarmonaM.PecceuF.CombesT.Poinot-ChazelC.CalandraB.et al. (1999). SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol. Exp. Ther.288, 582–589.
18
SchuehlyW.ParedesJ. M.KleyerJ.HuefnerA.Anavi-GofferS.RadunerS.et al. (2011). Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem. Biol.18, 1053–1064. 10.1016/j.chembiol.2011.05.012
19
ShonbergJ.HerenbrinkC. K.LópezL.ChristopoulosA.ScammellsP. J.CapuanoB.et al. (2013). A structure–activity analysis of biased agonism at the dopamine D2 receptor. J. Med. Chem.56, 9199–9221. 10.1021/jm401318w
20
SoethoudtM.GretherU.FingerleJ.GrimT. W.FezzaF.de PetrocellisL.et al. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat. Commun.8:13958. 10.1038/ncomms13958
21
ValantC.GregoryK. J.HallN. E.ScammellsP. J.LewM. J.SextonP. M.et al. (2008). A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem.283, 29312–29321. 10.1074/jbc.M803801200
22
van der SteltM.CalsJ.Broeders-JostenS.CottneyJ.van der DoelenA. A.HermkensM.et al. (2011). Discovery and optimization of 1-(4-(Pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. J. Med. Chem.54, 7350–7362. 10.1021/jm200916p
23
WrightK.RooneyN.FeeneyM.TateJ.RobertsonD.WelhamM.et al. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology129, 437–453. 10.1016/j.gastro.2005.05.026
24
YrjöläS.SarparantaM.AiraksinenA. J.HyttiM.KauppinenA.Pasonen-SeppänenS.et al. (2015). Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. Eur. J. Pharm. Sci.67, 85–96. 10.1016/j.ejps.2014.11.003
Summary
Keywords
cannabinoid receptor 2 (CB2), G protein-coupled receptor, signalling bias, signalling, synthetic cannabinoid, drug design, medicinal chemistry, immune therapeutics
Citation
Frontiers Production Office (2019) Erratum: Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines. Front. Pharmacol. 10:418. doi: 10.3389/fphar.2019.00418
Received
28 March 2019
Accepted
03 April 2019
Published
05 April 2019
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
10 - 2019
Updates
Copyright
© 2019 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office production.office@frontiersin.org
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.